Quantcast

Industry news that matters to you.  Learn more

Archives for March 2014

CBSET Scientists Indicate Mechanistic Preclinical Research is Critical to the Future of Renal Denervation

Scientists at CBSET, a not-for-profit preclinical research institute dedicated to biomedical research, education, and advancement of medical technologies, are reminding thought leaders in renal denervation that there is a seminal experimental and computational template for the more rational, comprehensive preclinical evaluation and optimization of renal denervation devices that can be utilized during preclinical and clinical development.

Genomic Health Announces Presentation of New Data Further Supporting Use of Oncotype DX in Europe

Genomic Health, Inc. (Nasdaq: GHDX) recently announced the presentation of multiple Oncotype DX® breast cancer studies at the 9th European Breast Cancer Conference (EBCC-9), which took place March 19-21 in Glasgow, Scotland, United Kingdom. New data included an independently conducted physician survey that underscores the need for broader availability of standard predictive genomic testing, like Oncotype DX, to help better inform chemotherapy treatment decisions in early-stage breast cancer patients in Europe. Additional studies showcasing the unsurpassed volume and consistency of clinical validation, clinical utility and health-economics evidence supporting the use of Oncotype DX were also  presented at the meeting.

Volcano Announces FDA Clearance of its Proprietary iFR (instant wave-Free Ratio) Modality and Immediate Commencement of U.S. Limited Market Release

Volcano Corporation (NASDAQ: VOLC) a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, recently announced FDA clearance of its proprietary instant wave-Free Ratio™ or iFR® Modality.

The New York Genome Center And IBM Watson Group Announce Collaboration To Advance Genomic Medicine

The New York Genome Center (NYGC) and IBM (NYSE: IBM) recently announced an initiative to accelerate a new era of genomic medicine with the use of IBM’s Watson cognitive system. IBM and NYGC will test a unique Watson prototype designed specifically for genomic research as a tool to help oncologists deliver more personalized care to cancer patients.

Shrink Wrap Used to Enhance Detection of Infectious Disease Biomarkers

Detecting HIV/AIDS, tuberculosis, malaria and other deadly infectious diseases as early as possible helps to prevent their rapid spread and allows for more effective treatments. But current detection methods are cost-prohibitive in most areas of the world. Now a new nanotechnology method—employing common, everyday shrink wrap—may make highly sensitive, extremely low-cost diagnosis of infectious disease agents possible.